Innovent Biologics has dosed the first patient in a phase 1 trial of IBI302, the company’s wet age-related macular degeneration treatment candidate, according to a press release.
A single intravitreal injection of IBI302, a recombinant fully human bispecific fusion protein targeting VEGF and complement proteins, will be evaluated in 36 patients with wet AMD in the open-label, single-center, dose escalation clinical trial.
“As the world’s first antibody-like bispecific fusion complement protein for ocular fundus diseases, IBI302 is designed to cure AMD by attacking its root
Uncategorized